Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL

from IMPACT Medicom · host IMPACT Medicom

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma. Our GuestDr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.This podcast episode was sponsored by Pfizer Canada Inc.If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

Episode metadata supplied by the publisher feed · Published Mar 26, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Management of Peripheral Neuropathy Associated with Brentuximab Vedotin in cHL

0:00 19:42

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of IMPACT Medicom?

This episode is 19 minutes long.

When was this IMPACT Medicom episode published?

This episode was published on March 26, 2025.

Can I download this IMPACT Medicom episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!